The PFS to EGFR-tyrosine kinase inhibitors in patients harboring ROS1 rearrangement was shorter than those without ROS1/ALK rearrangement (2.5 versus 7.8 months.     ///    P = 0.008) to pemetrexed than those without ROS1/ALK rearrangement. 